New biosimilar aims to match cancer drug OPDIVO at lower cost
NCT ID NCT07518043
First seen Apr 10, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the drug moves through the body, its safety, and its ability to prevent cancer from coming back. The study is not yet recruiting and is still in early stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX18 (a biosimilar drug similar to nivolumab/OPDIVO)
What this could lead to
If successful, this could show that HLX18 works as well as OPDIVO, potentially offering a more affordable treatment option for certain cancers after surgery.
What could go wrong
This is an early Phase 1 study with only 174 participants, so results may not confirm effectiveness. The drug is a biosimilar, meaning it may not perform identically to the original, and side effects could be similar to OPDIVO, including immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.